| Des-acyl ghrelin reduces alcohol intake and alcohol-induced reward in rodents S Witley, CE Edvardsson, C Aranäs, M Tufvesson-Alm, D Stalberga, ... Translational Psychiatry 14 (1), 277, 2024 | | 2024 |
| In vitro cannabinoid activity profiling of generic ban‐evading brominated synthetic cannabinoid receptor agonists and their analogs MH Deventer, M Persson, C Norman, H Liu, MJ Connolly, NN Daéid, ... Drug Testing and Analysis 16 (6), 616-628, 2024 | 2 | 2024 |
| Human metabolism of the semi‐synthetic cannabinoids hexahydrocannabinol, hexahydrocannabiphorol and their acetates using hepatocytes and urine samples K Lindbom, C Norman, S Baginski, L Krebs, D Stalberga, T Rautio, X Wu, ... Drug Testing and Analysis, 2024 | 1 | 2024 |
| Postmortem metabolomics as a high-throughput cause-of-death screening tool for human death investigations LJ Ward, S Kling, G Engvall, C Söderberg, FC Kugelberg, H Green, ... Iscience 27 (5), 2024 | | 2024 |
| Prediction models of persistent taxane-induced peripheral neuropathy among breast cancer survivors using whole-exome sequencing K Engvall, H Uvdal, N Björn, E Åvall-Lundqvist, H Gréen NPJ Precision Oncology 8 (1), 102, 2024 | | 2024 |
| Quantitation of hexahydrocannabinol (HHC) and metabolites in blood from DUID cases R Kronstrand, M Roman, H Green, MT Truver Journal of Analytical Toxicology 48 (4), 235-241, 2024 | 1 | 2024 |
| Characterization of neurotransmitter inhibition for seven cathinones by a proprietary fluorescent dye method M Persson, S Vikingsson, R Kronstrand, H Green Drug Testing and Analysis 16 (4), 339-347, 2024 | 5 | 2024 |
| Biomarkers and Proteomics in Sarcomeric Hypertrophic Cardiomyopathy in the Young—FGF-21 Highly Associated with Overt Disease AW Österberg, I Östman-Smith, H Green, C Gunnarsson, M Fredrikson, ... Journal of cardiovascular development and disease 11 (4), 105, 2024 | | 2024 |
| Enhancer mutations modulate the severity of chemotherapy-induced myelosuppression A Zhigulev, Z Norberg, J Cordier, R Spalinskas, H Bassereh, N Björn, ... Life Science Alliance 7 (3), 2024 | 1 | 2024 |
| Pharmacological profile, phase I metabolism, and excretion time profile of the new synthetic cathinone 3, 4‐Pr‐PipVP HM Schwelm, M Persson, B Pulver, MV Huß, H Gréen, V Auwärter Drug Testing and Analysis 16 (3), 277-288, 2024 | 1 | 2024 |
| Whole genome case-control study of central nervous system toxicity due to antimicrobial drugs J Ås, I Bertulyte, N Norgren, A Johansson, N Eriksson, H Green, ... Plos one 19 (2), e0299075, 2024 | | 2024 |
| CYP2D6 Genotyping and Inhibition as Predictors of Adverse Drug Reactions in Depressive Disorders A Holck, M Asp, H Green, Å Westrin, M Reis The Journal of clinical psychiatry 85 (1), 51095, 2024 | 1 | 2024 |
| In vitro activation of the CB1 receptor by the semi‐synthetic cannabinoids hexahydrocannabinol (HHC), hexahydrocannabinol acetate (HHC‐O) and … M Persson, R Kronstrand, M Evans‐Brown, H Green Drug Testing and Analysis, 2024 | | 2024 |
| Log D7.4 and plasma protein binding of synthetic cannabinoid receptor agonists and a comparison of experimental and predicted lipophilicity AM Brandon, SR Baginski, C Peet, P Dugard, H Green, OB Sutcliffe, ... Drug Testing and Analysis, 2023 | | 2023 |
| Impact of resection margins and para-aortic lymph node metastases on recurrence patterns and prognosis in resectable pancreatic cancer–a long-term population-based cohort study H Blomstrand, H Olsson, H Green, B Björnsson, NO Elander HPB 25 (12), 1531-1544, 2023 | 3 | 2023 |
| Detection in seized samples, analytical characterization, and in vitro metabolism of the newly emerged 5‐bromo‐indazole‐3‐carboxamide synthetic cannabinoid receptor agonists C Norman, K Webling, O Kyslychenko, R Reid, AJ Krotulski, R Farrell, ... Drug Testing and Analysis, 2023 | 2 | 2023 |
| The metabolic profile of the synthetic cannabinoid receptor agonist ADB-HEXINACA using human hepatocytes, LC–QTOF-MS and synthesized reference standards SR Baginski, T Rautio, LA Nisbet, K Lindbom, X Wu, J Dahlén, ... Journal of Analytical Toxicology 47 (9), 826-834, 2023 | 5 | 2023 |
| Rilmazafone: A designer benzodiazepine pro-drug involved in fatal intoxications R Kronstrand, M Roman, A Johansson, X Wu, H Green, MT Truver Journal of Analytical Toxicology 47 (7), 640-643, 2023 | | 2023 |
| Intralipid as a matrix additive for evaluating hyperlipidemic postmortem blood E Elenstål, H Green, R Kronstrand, A Elmsjö Journal of Analytical Toxicology 47 (6), 529-534, 2023 | | 2023 |
| Using in vitro receptor activity studies of synthetic cannabinoids to support the risk assessment of new psychoactive substances–A Swedish strategy to protect public health … M Bäckberg, S Vikingsson, J Strandberg, S Wall, A Åstrand, H Karlsson, ... Forensic science international 348, 111691, 2023 | 2 | 2023 |
